AI Article Synopsis
Article Abstract
Objective: To investigate the potential impact of aromatase inhibitors, given after stopping tamoxifen treatment, on the endometrium of postmenopausal breast cancer patients.
Methods: Review of all available literature of studies on aromatase inhibitor therapy in postmenopausal breast cancer patients previously treated with tamoxifen.
Results: (1) Endometrial thickness was found to be significantly lower in patients switched from tamoxifen treatment to aromatase inhibitor therapy, compared to those who continued tamoxifen treatment. This significant difference between the 2 groups was maintained throughout the entire treatment. (2) Vaginal bleeding was significantly more common in patients who continued tamoxifen therapy as compared to those who switched to aromatase inhibitors. (3) Replacement of tamoxifen treatment by aromatase inhibitors in postmenopausal breast cancer patients resulted in the appearance of only few, benign endometrial pathologies. The different endometrial pathologies were more common in patients who continued tamoxifen therapy, compared to patients who switched to aromatase inhibitors. (4) Endometrial cancer was recovered in significantly more patients who continued tamoxifen therapy as compared to those switched to aromatase inhibitors. However, some studies showed no significant statistical differences in the frequency of endometrial cancer diagnosed in the tamoxifen group as compared to the aromatase inhibitor group.
Conclusion: These findings may hint on the possibility that aromatase inhibitors may provide a potential protective effect on the endometrium in patients previously treated with tamoxifen.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.maturitas.2008.03.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Web-based pain coping skills training (PCST) for managing aromatase inhibitor-associated arthralgia in breast cancer survivors: Randomized controlled trial protocol.
Contemp Clin Trials
December 2024
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, United States of America; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, United States of America. Electronic address:
Background: Aromatase inhibitors (AIs) are a cornerstone of adjuvant systemic therapy for postmenopausal patients with hormone-receptor positive (HR+) breast cancer. Although AIs decrease cancer recurrence rates and improve survival rates, approximately 50 % of patients experience arthralgia-persistent pain related to worse patient outcomes and poor AI adherence. Current medical interventions for AI-associated arthralgia have limited efficacy and side effects that restrict their use among older patients.
View Article and Find Full Text PDF[Mechanism of Yuzhi Zhixue Granules in treating polycystic ovary syndrome in rats].
Zhongguo Zhong Yao Za Zhi
October 2024
School of Pharmacy, Shandong University of Traditional Chinese Medicine Ji'nan 250355, China State Key Laboratory of Integration and Innovation of Classic Formula and Modern Chinese Medicine, Lunan Pharmaceutical Group Co., Ltd. Linyi 273400, China.
This study aims to explore the therapeutic effect of Yuzhi Zhixue Granules on polycystic ovary syndrome(PCOS) in rats and explain the underlying mechanism by metabolomics. Rats were randomized into normal, model, low-, medium-, and high-dose(0.5, 1.
View Article and Find Full Text PDFAromatase inhibitors for short stature in male children and adolescents treated with growth hormone: a meta-analysis of randomized controlled trials.
BMC Pediatr
December 2024
Jinhua Maternity and Child Health Care Hospital, Jinhua Women and Children's Hospital, Jinhua, 322199, China.
Whether the addition of aromatase inhibitors (AIs) to recombinant human growth hormone (rhGH) could yield additional benefit for short stature is controversial. We aimed to assess the effects of combined AIs and rhGH versus those of rhGH alone for short stature using a meta-analytic approach. The PubMed, Embase, and the Cochrane library electronic databases were searched systematically for eligible randomized controlled trials (RCTs) from inception until December 2021.
View Article and Find Full Text PDFAbemaciclib Plus Fulvestrant in Advanced Breast Cancer Following Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial.
J Clin Oncol
December 2024
Massachusetts General Hospital, Harvard University, Boston, MA, USA.
Purpose: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are the standard first-line treatment for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC); however, disease progression occurs in almost all patients and additional treatment options are needed. Herein we report outcomes of the postMONARCH trial investigating a switch in ET with/without CDK4/6 inhibition with abemaciclib after disease progression on CDK4/6i.
Methods: This double-blind, randomized Phase III study enrolled patients with disease progression on prior CDK4/6i plus aromatase inhibitor as initial therapy for advanced disease or recurrence on/after adjuvant CDK4/6i+ET.
Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer.
J Cachexia Sarcopenia Muscle
December 2024
Department of Internal Medicine, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Background: Recent evidence indicates that a dysregulated host metabolism influences treatment outcomes in patients with breast cancer. We investigated the association of computed tomography (CT)-derived body composition indices with therapeutic responses in patients with hormone receptor-positive, HER2-negative advanced breast cancer (ABC) on endocrine plus CDK4/6 inhibitor (CDK4/6i) treatment.
Methods: The study involved a retrospective cohort of patients with ABC at the Yonsei Cancer Center who received CDK4/6i and aromatase inhibitors as first-line therapy between January 2017 and October 2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!